236 related articles for article (PubMed ID: 31446509)
1. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer.
Agarwal M; Canan T; Glover G; Thareja N; Akhondi A; Rosenberg J
Curr Oncol Rep; 2019 Aug; 21(10):91. PubMed ID: 31446509
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
[TBL] [Abstract][Full Text] [Related]
3. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
4. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
7. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
Shao YJ; Hong JH; Chen CK; Huang CY
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
[TBL] [Abstract][Full Text] [Related]
9. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
Lowentritt B; Fallick M; Pruett J; Jiang T; Li E; Brown B; Dufour R
Urol Pract; 2024 Jan; 11(1):154-161. PubMed ID: 37914225
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.
Lafontaine ML; Kokorovic A
Curr Opin Support Palliat Care; 2022 Dec; 16(4):216-222. PubMed ID: 36349380
[TBL] [Abstract][Full Text] [Related]
12. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicity of Androgen Deprivation Therapy.
Boland J; Choi W; Lee M; Lin J
Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
[TBL] [Abstract][Full Text] [Related]
17. [Antihormonal therapy in prostate cancer : Side effects].
Ohlmann CH; Thelen P
Urologe A; 2017 Apr; 56(4):465-471. PubMed ID: 28246761
[TBL] [Abstract][Full Text] [Related]
18. Hormonal prostate cancer therapies and cardiovascular disease: a systematic review.
Cereda V; Falbo PT; Manna G; Iannace A; Menghi A; Corona M; Semenova D; Calò L; Carnevale R; Frati G; Lanzetta G
Heart Fail Rev; 2022 Jan; 27(1):119-134. PubMed ID: 32500365
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
20. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.
George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M
Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
